Infectious Disease
Infectious disease guidance, antimicrobial updates, safety signals and trial intelligence for clinicians managing changing pathogens, resistance and immunisation evidence.
Latest Guidelines
Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula
Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a targeted intervention when conservative management has…
2022 ESCMID Guidelines on Candidaemia and Invasive Candidiasis
This ESCMID guideline addresses 2022 ESCMID Guidelines on Candidaemia and Invasive Candidiasis in Infectious Disease. Use it to review current recommendation wording, eligibility criteria, and implementation…
HIV Testing: Increasing Uptake Among People Who May Have Undiagnosed HIV (NICE PH33)
Offer opt-out HIV testing in emergency departments, sexual health clinics, and antenatal services to maximise identification of undiagnosed HIV cases without requiring explicit patient consent Implement…
COVID-19: Managing the Long-Term Effects (NICE NG188)
Diagnose long COVID when symptoms persist for more than 4 weeks after acute COVID-19 infection and alternative diagnoses have been excluded; undertake baseline assessment including FBC,…
Tuberculosis (NICE NG33)
Offer TB testing to all contacts of patients with active pulmonary or laryngeal TB within two weeks of case notification using IGRA (preferred) or TST to…
Cellulitis and Erysipelas: Antimicrobial Prescribing (NICE NG141)
For non-severe cellulitis in adults, prescribe oral flucloxacillin 500 mg four times daily; use cephalexin 500 mg four times daily if penicillin-allergic • For severe cellulitis…
Trial Radar
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
What is being tested: Cabotegravir ultra long-acting (CAB ULA) plus rilpivirine ultra-acting (RPV ULA) injections are being compared…
TrialRegistry of GORE® ACUSEAL Vascular Graft in Dialysis Access
What is being tested: Safety and performance of GORE® ACUSEAL Vascular Graft, a synthetic vascular access device for…
PHASE2Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
AZD5148 antibody reduces repeat Clostridioides difficile infections in adults compared to placebo.
PHASE3A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn’s Disease
Risankizumab maintains remission in moderate-to-severe Crohn's disease; studies examine dosing schedules, long-term safety, and injection device preferences.
Clinical News
People Fixing The World
Sepsis Prevention, Detection and Treatment Early recognition is critical – Sepsis remains a major cause of mortality and…
31 Aug 2026New super flu vaccine rollout begins as NHS regroups from ‘busiest summer’
The NHS is rolling out an updated flu vaccine this season with modifications designed to improve protection against…
26 Aug 2026Heavy periods study to create world’s largest biobank
A new biobank of menstrual fluid samples is being established to identify biomarkers and improve understanding of heavy…
19 Aug 2026Salmonella outbreak: What we know so far
Salmonella outbreak affecting hundreds linked to imported eggs—maintain high clinical suspicion for salmonellosis in patients presenting with gastroenteritis…
Relevant Mechanisms
CPD, Podcasts & Webinars
Follow Infectious Disease safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Infectious Disease
Choose guideline, trial, Drug Science and education updates for this specialty.